斯克菲尔的个人博客
scac · 2007-09-24
<< To Learn More About This Topic and ok
|
首 页
|
Last Updated: 2007-09-24 12:34:14 -0400 (Reuters Health) >>
What is cervical cancer
- [
other
]
2007-10-29
分类:
other
版权声明
:转载时请以超链接形式标明文章原始出处和作者信息及
本声明
http://scac.blogbus.com/logs/10538416.html
Cancer is a disease in which certain body cells don't function right, divide very fast, and produce too much tissue that forms a tumor. Cervical cancer is cancer in the cervix, the lower, narrow part of the uterus (womb). The uterus is the hollow, pear-shaped organ where a baby grows during a woman's pregnancy. The cervix forms a canal that opens into the vagina (birth canal), which leads to the outside of the body.
If the Pap test finds serious changes in the cells of the cervix, the doctor will suggest more powerful tests such as a coloscopy. In this procedure, the doctor uses a tool called a colposcope to see the cells of the vagina and cervix in detail.
If there are still some concerns of precancerous cells, the doctor may use the LUMA Cervical Imaging System. The doctor uses this device right after a colposcopy. This system, recently approved by the FDA, shines a light on the cervix and looks at how different areas of the cervix respond to this light. It gives a score to tiny areas of the cervix. It then makes a color map that helps the doctor decide where to further test the tissue with a biopsy. The colors and patterns on the map help the doctor tell between healthy tissue and tissue that might be diseased.
Why should I be concerned about cervical cancer?
Cervical cancer is a disease that can be very serious. However, it is a disease that you can help prevent. Cervical cancer occurs when normal cells in the cervix change into cancer cells. This normally takes several years to happen, but it can also happen in a very short period of time. The good news is that there are ways to help prevent cervical cancer. By getting regular Pap tests and pelvic exams, your health care provider can find and treat the changing cells before they turn into cancer.
<!-- Inject Script Filtered -->
value is 27, again well outside the human range.
For maximum distances, the maximum such value is 24, but for most humans, the maximum distance to any other human will be less than that. The value of 24 is highly atypical, because it is taken between the two individuals who have indepently diverged farthest from mitochondrial Eve, and is the maximum of nearly half a million (994 * 993 / 2) comparisons among modern humans. For the Neandertal, the value is 36, again well outside the human range.
In other words, for all three measurements (minimum, average and maximum distances to other humans), the Neandertal measurement is much larger than the maximum value of the same measurement from a sample of 994 modern humans, and even further from the average value. The Neandertal is not merely outside the human range, but well outside it.
Possible problems
The use of mitochondrial mtDNA to investigate human history is not without drawbacks.
The rate of mtDNA mutation is not well known. A study by Parsons et al. (1997) found a rate 20 times higher than that calculated from other sources. In an article reviewing mtDNA research, Strauss (1999a) reports that mtDNA mutation rates differ in some groups of animals, and can even vary dramatically in single lineages. Although there are many agreements, some divergence dates for modern animals calculated from mtDNA do not match with what is known from the fossil record. There are suggestions from a few sources that paternal mtDNA can sometimes be inherited, which could affect analyses based on mtDNA.
In 1999 Awadalla et al. published a study suggesting that mtDNA could sometimes be inherited from fathers. If mtDNA is inherited only from mothers, the correlation between different mutations should not depend on how far apart on the genome they were. Instead, their measurements showed that mutations at distant sites on the mtDNA genome were less likely to be correlated than nearby mutations, suggesting that mtDNA from mothers and fathers could sometimes get mixed. However, there is no explanation so far as to how this recombination could be occurring, and the possibility that other phenomena could be causing this effect has not yet been disproved. If it occurs, mixing would mean that the dates from current mtDNA studies would be too old. If mixing is common enough, it could even mean that there was no mitochondrial Eve, because different parts of the mtDNA molecule would have different histories. (Awadalla et al. 1999, Strauss 1999b) Other studies, however, have contradicted these results and argued for strictly maternal mtDNA inheritance (Elson et al. 2001), and, according to Sykes (2001), the Awadalla paper and another paper which also suggested that mtDNA could be inherited paternally were based on incorrect data and were later retracted.
Conclusions
The studies of Neandertal mtDNA do not show that Neandertals did not or could not interbreed with modern humans. However, the lack of diversity in Neandertal mtDNA sequences, combined with the large differences between Neandertal and modern human mtDNA, strongly suggest that Neandertals and modern humans developed separately, and did not form part of a single large interbreeding population. The Neandertal mtDNA studies will strengthen the arguments of those scientists who claim that Neandertals should be considered a separate species which did not significantly contribute to the modern gene pool.
References
Anderson S., Bankier A.T., Barrel B.G., de Bruijn M.H.L., Coulson A.R., Drouin J. et al. (1981): Sequence and organization of the human mitochondrial genome. Nature, 290:457-74.
Awadalla P., Eyre-Walker A., and Smith J.M. (1999): Linkage disequilibrium and recombination in hominid mitochondrial DNA. Science, 286:2524-5.
Elson J.L., Andrews R.M., Chinnery P.F., Lightowlers R.N., Turnbull D.M., and Howell N. (2001): Analysis of European mtDNAs for recombination. American Journal of Human Genetics, 68:145-53.
Höss M. (2000): Neanderthal population genetics. Nature, 404:453-4.
Kahn P. and Gibbons A. (1997): DNA from an extinct human. Science, 277:176-8.
Knight A. (2003): The phylogenetic relationship of Neandertal and modern human mitochondrial DNAs based on informative nucleotide sites. Journal of Human Evolution, 44:627-32.
Krings M., Capelli C., Tschentscher F., Geisert H., Meyer S., von Haeseler A. et al. (2000): A view of Neandertal genetic diversity. Nature Genetics, 26:144-6.
Krings M., Geisert H., Schmitz R.W., Krainitzki H., and Pääbo S. (1999): DNA sequence of the mitochondrial hypervariable region II from the Neandertal type specimen. Proceedings of the National Academy of Sciences, USA, 96:5581-5.
Krings M., Stone A., Schmitz R.W., Krainitzki H., Stoneking M., and Pääbo S. (1997): Neandertal DNA sequences and the origin of modern humans. Cell, 90:19-30.
Ovchinnikov I.V., Götherström A., Romanova G.P., Kharitonov V.M., Lidén K., and Goodwin W. (2000): Molecular analysis of Neanderthal DNA from the northern Caucasus. Nature, 404:490-3.
Parsons T.J., Muniec D.S., Sullivan K., Woodyatt N., Alliston-Greiner R., Wilson M.R. et al. (1997): A high observed substitution rate in the human mitochondrial DNA control region. Nature Genetics, 15:363-8.
Schmitz R.W., Serre D., Bonani G., Feine S., Hillgruber F., Krainitzki H. et al. (2002): The Neandertal type site revisited: Interdisciplinary investigations of skeletal remains from the Neander Valley, Germany. Proceedings of the National Academy of Sciences, USA, 99:13342-7.
Serre D., Langaney A., Chech M., Teschler-Nicola M., Paunovic M., Mennecier P. et al. (2004): No evidence of Neandertal mtDNA contribution to early modern humans. PLoS Biology, 2:313-7.
Strauss E. (1999a): Can mitochondrial clocks keep time? Science, 283:1435
Strauss E. (1999b): mtDNA shows signs of paternal influence. Science, 286:2436
Sykes B. (2001): The seven daughters of Eve. London: Bantam Press. (a good popular book about mitochondrial DNA)
Ward R. and Stringer C.B. (1997): A molecular handle on the Neanderthals. Nature, 388:225-6.
If you've been diagnosed with early breast cancer, a lot of your treatment plan is aimed at reducing the risk of the cancer coming back (recurrence). Chemotherapy, targeted therapy, radiation therapy, and hormonal therapy given before or after surgery are all used to lower your risk of recurrence.
Better ways to determine the risk of recurrence would allow doctors to create treatment plans tailored to each woman's individual recurrence risk. So if there were a test that told you and your doctor that your recurrence risk was very low, you might decide to skip chemotherapy after surgery. Right now, some breast cancer characteristics -- such as grade and stage -- offer a rough estimate of your recurrence risk, but it's not as precise as anyone would like.
The study reviewed here offers hope that doctors eventually may be able to estimate anyone's risk of recurrence with more precision, allowing treatment to be tailored to individual risk. The researchers suspect that if circulating tumor cells (CTCs) are in the blood before and after chemotherapy given after surgery, the risk of recurrence is high. If CTCs are not in the blood before and after chemotherapy, the risk of recurrence is low. Still, this study doesn't prove that a CTC test would offer a more accurate estimate of recurrence risk.
There are two tests available that look at the genetic make-up of the breast cancer and use that information to predict recurrence. Those tests are the
Oncotype DX
and the
MammaPrint
. The Oncotype DX test is used to develop recurrence scores for lymph node-negative, estrogen-receptor-positive, early breast cancers. The MammaPrint test is used to develop recurrence scores for lymph node-negative, early breast cancers. Both of these tests are relatively new and have been tested on relatively small groups of women. Both tests cost more than $3,000.
Each woman's breast cancer situation is different. In addition to cancer characteristics, recurrence tests may give you and your doctor one more piece of information that you can use to make treatment decisions. If you've been diagnosed with node-negative, early breast cancer, talk to your doctor to see if a recurrence test makes sense for you. And stay tuned to breastcancer.org for the latest updates on new tests that will help ensure the best treatment for YOU.
相关文章:
DNA, RNA, and Protein: Life at its simplest
2007-11-10
about mba
2007-11-01
Last Updated: 2007-09-24 12:34:14 -0400 (Reuters Health)
2007-10-29
To Learn More About This Topic and ok
2007-10-29
IESuper(IE超人) V1.0.1.3
2007-10-29
收藏到:
Del.icio.us
Tag:
引用地址:
scac
发表于
11:32:47
|
编辑
|
继续话题
|
转发
|
推荐
发表评论
原始快照:web.archive.org